room air between interventions, resulting in low probability of contamination between sequential experimental conditions. Sufficient time to ensure that the particle concentrations return to baseline is necessary between interventions in future studies, especially if frequent air exchange is not available.

Optimal respiratory management of patients suffering from COVID-19 pneumonia is debated; the potential benefits of early intubation, NIV, and HFNC, to be put into balance with the potential risk of bioaerosol generation and dispersion, are controversial; and practice is heterogeneous between units and over time during the pandemic spread (13, 14). As evidence is accumulating against a significantly increased bioaerosol generation associated with the use of HFNC and NIV, clinicians may consider those therapeutic options as they do when caring for patients with hypoxemia without COVID-19, not overemphasizing the potential theoretical risk of increased infectious transmission. In any case, personal protective equipment should be worn by professionals caring for patients with suspected or confirmed COVID-19.

Beyond bioaerosol generation and dispersion, the crucial question that needs to be answered remains the infectious potential of the virus carried by the bioaerosols generated by the patients or various procedures and its relative quantitative importance compared with other routes of viral dissemination such as surface contact.

Author disclosures are available with the text of this article at www.atsjournals.org.

References
1. ICNARC report on COVID-19 in critical care. [accessed 2020 Aug 22]. Available from: https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports.
2. Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-generating medical procedures. Viruses 2019;11:940.
3. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One 2012;7:e35797.
4. Gaeckle NT, Lee J, Park Y, Kreykes G, Evans MD, Hogan CJ Jr. Aerosol generation from the respiratory tract with various modes of oxygen delivery. Am J Respir Crit Care Med 2020;202:1115–1124.
5. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J 2020;55:2000892.
6. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J 2019;53:1802339.
7. Hui DS, Chow BK, Ng SS, Chu LCY, Hall SD, Gih T, et al. Exhaled air dispersion distances during noninvasive ventilation via different Respicore face masks. Chest 2009;136:998–1005.
8. Tang JW, Settles GS. Images in clinical medicine: coughing and aerosols. N Engl J Med 2008;359:e19.
9. Anfinrud P, Stadnytskiy V, Bax CE, Bax A. Visualizing speech-generated oral fluid droplets with laser light scattering. N Engl J Med 2020;382:2061–2063.
10. Dhand R, Li J. Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med 2020;202:651–659.
11. Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. Lancet Respir Med [online ahead of print] 24 Jul 2020. DOI: 10.1016/S2213-2600(20)30323-4.
12. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564–1567.
13. Demoule A, Vieillard Baron A, Darmon M, Beurton A, Géri G, Voiriot G, et al. High flow nasal cannula in critically ill severe COVID-19 patients. Am J Respir Crit Care Med [online ahead of print] 6 Aug 2020; DOI: 10.1164/rcrm.202006-2007LE.
14. Hernandez-Romieu AC, Adelman MW, Hickstein MA, Robichaux CJ, Edwards JA, Fazio JC, et al.; Emory COVID-19 Quality and Clinical Research Collaborative. Timing of intubation and mortality among critically ill coronavirus disease 2019 patients: a single-center cohort study. Crit Care Med [online ahead of print] 14 Aug 2020; DOI: 10.1097/ CCM.0000000000004660.

Copyright © 2020 by the American Thoracic Society

Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia: The Hidden Enemy?

Ventilator-associated pneumonia (VAP) is one of the most important hospital-acquired infections in mechanically ventilated patients. It has a major impact in terms of morbidity, mortality, and health costs.

The microbiology of bacterial VAP has been well established by studies using standard quantitative or semi-quantitative microbiological techniques in either distal (BAL) or proximal samples (endotracheal aspirates) (1). The few studies to include rapid molecular techniques have demonstrated an increased rate of microbial diagnoses compared with standard methods (2). Fungi, and especially Aspergillus species, are recognized as a potential cause of VAP in nonimmunosuppressed patients. However, the most recent guidelines do not provide recommendations for their suspicion and diagnosis (3, 4), nor do
Aspergillus | October 15 2020

conidia enhances Aspergillus fumigatus Geotrichum capsulatum VAP when added to cultures and GM in BAL. In the were not fi...as a potential cause of...in all 24...is a more...species 1072 (GM) and 1,3-...the detection of fungal cell wall co...death (5). Additional tests may in...aspergillosis to be the most freque...invasion (Figure 1). Understanding the pathophysiological mechanisms of fungal colonization is essential to develop strategies able to avert the disease.

The diagnosis of invasive pulmonary aspergillosis is based on cultures of clinical samples and on the detection of fungal elements (hyphae) in histopathological examination in primarily sterile specimens, independently of the culture results. Unfortunately, this is not possible in mechanically ventilated critically ill patients, which is why autopsy studies of mechanically ventilated patients have found aspergillosis to be the most frequently neglected potential cause of death (5). Additional tests may include nonculture methods, such as the detection of fungal cell wall components. Galactomannan antigens (GM) and 1,3-β-D-glucan circulating in serum and BAL are useful for the diagnosis of invasive aspergillosis. However, because of a variety of factors, there is a possibility of false-positive or false-negative results (6). False positives may be a consequence of using antibiotics such as β-lactams (piperacillin with tazobactam) and other drugs (immunoglobulin, cyclophosphamide, and plasma-like products).

Patients infected with other fungal species (Penicillium marneffei, Cryptococcus neoformans, Geotrichum capsulatum, Histoplasma capsulatum, or Lichtheimia ramosa) or with Bifidobacterium species have also been reported as cases of cross reactions (7).

In this issue of the Journal, Loughlin and colleagues (pp. 1125–1132) (8) present the retrospective results of a multicenter UK study of two cohorts of patients with suspected VAP. The same methodology was applied in 194 nonimmunosuppressed patients, which included BAL with stains and semiquantitative standard cultures for bacteria and fungi. Significantly, the authors measured GM in BAL and in serum. The definition of probable Aspergillus infections required one of the following: positive microscopy or histology, a positive BAL fluid culture, and a GM optical index ≥1 in BAL or in serum. Using this systematic definition, the authors found a prevalence of Aspergillus VAP of 12.4%, a figure far higher than those reported in previous epidemiological studies in which the prevalence of the condition was anecdotal or very low.

How Can We Explain These Findings?

1) In previous studies, systematic searches for Aspergillus were not performed; investigators relied only on stains and cultures and on autopsy findings. Quantitative or semiquantitative cultures were also not performed.

2) Many studies were based only on endotracheal aspirates, which are not sensitive for detecting fungi in their cultures.

3) In nonsevere immunosuppressed patients, GM in BAL and serum is not measured and is not included in the diagnostic workup.

4) Clinicians do not include Aspergillus as a potential cause of VAP in nonsevere immunosuppressed patients.

The main lesson of this study is that Aspergillus is a more frequent cause of VAP in nonimmunosuppressed patients than clinicians may think. Second, applying nonculture methods such as GM in BAL and serum can diagnose some additional cases and thus save lives. The question that arises immediately is whether these procedures should be applied systematically in all cases of suspected VAP. The study under review was not designed to answer this question. The risk factors for Aspergillus VAP in nonimmunosuppressed patients are not well known but probably include long-term mechanical ventilation, previous antibiotic treatment, corticosteroid administration, and chronic lung comorbidities. In this study, corticosteroid treatment and chronic obstructive pulmonary disease were more frequent but nonsignificant in cases with presumptive diagnosis of Aspergillus.

Another point to establish is the extent to which rapid molecular techniques such as PCR might help in the diagnosis of Aspergillus VAP when added to cultures and GM in BAL. In the current study, PCR was positive in 10 out of the 24 patients in BAL and in 5 in serum, so it was not positive for Aspergillus in all 24 patients. This means that PCR should be performed together...
With cultures and GM for the diagnosis of Aspergillus VAP in nonimmunosuppressed patients. In any case, both cultures and PCR need quantification to rule out colonization.

A burning subject is Aspergillus VAP in ventilated patients with coronavirus disease (COVID-19). In this issue of the Journal, Van Biesen and colleagues (pp. 1171–1173) report the performance of nondirected BAL in a cohort of 42 ventilated patients with COVID-19 (9). Based on clinical symptoms and a positive GM testing on directed BAL fluid, the proportion of putative aspergillosis was 21.4%. Fungal cultures of the nondirected BAL yielded positive results in seven of the patients with clinical symptoms and positive GM (cutoff 1 optical index) (77.8%). Bronchoscopic BAL is the preferred method to measure GM in BAL. However, because of the risk of aerosolization in patients with COVID-19, nonbronchoscopic methods should be the preferred ones given the results of this study. In fact, this is the current recommendation of the American Association for Bronchology and Interventional Pulmonology (10). Probably the use of nondirected BAL may increase the risk of false positives.

In summary, the manuscript published by Loughlin and colleagues (8) provides some useful answers and poses interesting questions. On the one hand, the study warns us about the possibility of Aspergillus VAP in nonimmunosuppressed patients, a diagnosis that is frequently neglected. On the other, it draws attention to the matter of Aspergillus colonization, an issue that remains unresolved in this population. The second manuscript from Van Biesen and colleagues (9) recommends the use of nondirected BAL in mechanically ventilated patients with COVID-19 to minimize aerosolization but maintains a good performance for Aspergillus diagnosis (GM + cultures). ■

**References**

1. Fernández-Barat L, Motos A, Ranzani OT, Bassi GL, Aguilera Xiol E, Senussi T, et al. Diagnostic value of endotracheal aspirates sonication on ventilator-associated pneumonia microbiologic diagnosis. *Microorganisms* 2017:5:62.
2. Walter JM, Wunderink RG. Testing for respiratory viruses in adults with severe lower respiratory infection. *Chess* 2018:154: 1213–1222.
3. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society. *Clin Infect Dis* 2016:63: e61–e111.
4. Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). *Eur Respir J* 2017;50: 1700582.
5. Tejerina EE, Abril E, Padilla R, Rodriguez Ruiz C, Ballen A, Frutos-Vivar F, et al. Invasive aspergillosis in critically ill patients: an autopsy study. *Mycoses* 2019:62:673–679.
6. Hadrich I, Mary C, Makri F, Elloumi M, Dumon H, Ayadi A, et al. Comparison of PCR-ELISA and Real-Time PCR for invasive aspergillosis diagnosis in patients with hematological malignancies. *Med Mycol* 2011:49:489–494.
7. Martin-Loeches I, Antonelli M, Cuenca-Estrella M, Dimopoulos G, Einav S, De Waele JJ, et al. ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. *Intensive Care Med* 2019:45:789–805.
8. Loughlin L, Hellyer TP, White PL, McAuley DF, Conway Morris A, Posso RB, et al. Pulmonary aspergillosis in patients with suspected ventilator-associated pneumonia in UK ICUs. *Am J Respir Crit Care Med* 2020:202:1125–1132.
9. Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. Detection of invasive pulmonary aspergillosis in COVID-19 with nondirected BAL [letter]. *Am J Respir Crit Care Med* 2020: 202:1171–1173.
10. Wahidi MM, Lamb C, Murgu S, Musani A, Shojaee S, Sachdeva A, et al. American association for Bronchology and interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or confirmed COVID-19 infection. *J Bronchology Interv Pulmonol* [online ahead of print] 18 Mar 2020; DOI: 10.1097/LBR.0000000000000681.

**Author disclosures** are available with the text of this article at www.atsjournals.org.

Antoni Torres, M.D., Ph.D.
Hospital Clinic, IDIBAPS
Universitat de Barcelona
Barcelona, Spain

Universitat de Barcelona
Barcelona, Spain
CIBERes
Barcelona, Spain
and
ICREA, Institución Catalana de Investigación y Estudios Avanzados
Barcelona, Spain

Ignacio Martin-Loeches, M.D., Ph.D.
Hospital Clinic, IDIBAPS
Universitat de Barcelona
Barcelona, Spain

Multidisciplinary Intensive Care Research Organization (MICRO)
Department of Intensive Care Medicine, St. James’s University Hospital
Dublin, Ireland

Trinity Centre for Health Sciences
Dublin, Ireland

**ORCID ID:** 0000-0002-5834-4063 (I.M.-L.).